For me, a week isn’t complete without tidbits from Dr. Richard Lehman’s journal review blog for The BMJ.
This week he analyzes widely-reported results of studies on breast cancer and heart disease:
When I see a cancer trial in one of the top journals, I generally scan the abstract to see if there is anything of general interest or importance. I drew a complete blank with this one. “Among women with predominantly stage I HER2-positive breast cancer, treatment with adjuvant paclitaxel plus trastuzumab was associated with a risk of early recurrence of about 2%; 6% of patients withdrew from the study because of protocol-specified adverse events.” Um, compared with what? Well, with what might have happened otherwise, elsewhere, possibly. “We recognize that a prospective, randomized trial would have been the best option. However, we did not believe that such a design would have been feasible given the accumulating evidence from retrospective studies. Patients and their providers may have been unlikely to enroll in a trial that included a group in which patients would not receive trastuzumab. Some clinicians and investigators might have argued for a trial of trastuzumab alone versus trastuzumab plus chemotherapy, but there are limited data indicating that trastuzumab alone is an effective approach.” Aha, but isn’t that exactly why people do RCTs? Why does this trial—which is just a large case series—get space in the New England Journal? Any time your well conducted, randomized, double blind trial gets rejected by the NEJM, you might like to ask them.
And about a paper in The Lancet….
The Cholesterol Treatment Trialists’ Collaboration offer a paper on “Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174?000 participants in 27 randomised trials.” But although there is now some weak evidence LDL-C lowering with ezetimibe may improve cardiovascular outcomes, all the evidence in this review is about statins. These drugs certainly lower LDL-C and “These results indicate that, for each 1 mmol/L reduction in LDL cholesterol, statin therapy reduced major vascular events by about a fifth, major coronary events by a quarter, coronary revascularisations by a quarter, and ischaemic stroke by just under a fifth, and that these proportional reductions were similar in men and women, even though on average women had somewhat lower absolute cardiovascular risk in these trials.” But it’s not just pedantic obstinacy that makes me chary about putting all this down to LDL-C lowering. I’m worried that people will therefore carry on treating cholesterol as some kind of target independent from total cardiovascular risk, whereas we need always to obey the commandment “Treat to level of risk and not to level of risk factor.” And scientifically I still can’t understand how statins can produce marked improvements in acute events before they have had time to reduce LDL-C.
(Note: The original post at first ended with “HDL-C.” It has since been corrected to LDL-C, so I have changed the excerpt above accordingly.)
We should be paying Lehman tuition for the distance learning he provides each week.
———————
Tweet
Follow us on Twitter:
https://twitter.com/garyschwitzer
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Comments are closed.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like